Expression of recombinant Rhipicephalus (Boophilus) microplus, R. annulatus and R. decoloratus Bm86 orthologs as secreted proteins in Pichia pastoris by Canales, Mario et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
Expression of recombinant Rhipicephalus (Boophilus) microplus, R. 
annulatus and R. decoloratus Bm86 orthologs as secreted proteins in 
Pichia pastoris
Mario Canales1, José M Pérez de la Lastra1, Victoria Naranjo1, Ard M Nijhof2, 
Michelle Hope3, Frans Jongejan2,4 and José de la Fuente*1,5
Address: 1Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), Ronda de Toledo s/n, 13071 Ciudad Real, Spain, 2Utrecht 
Centre for Tick-borne Diseases (UCTD), Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 
Yalelaan 1, 3584CL, Utrecht, The Netherlands, 3CSIRO Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St. Lucia, Qld 
4067, Australia, 4Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, 0110, 
Onderstepoort, South Africa and 5Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, 
Stillwater, OK 74078, USA
Email: Mario Canales - mario.canales@uclm.es; José M Pérez de la Lastra - josemanuel.plastra@uclm.es; 
Victoria Naranjo - mvictoria.naranjo@uclm.es; Ard M Nijhof - A.M.Nijhof@uu.nl; Michelle Hope - Shelly.Hope@csiro.au; 
Frans Jongejan - Jongejan@uu.nl; José de la Fuente* - jose.de_la_fuente@okstate.edu
* Corresponding author    
Abstract
Background: Rhipicephalus (Boophilus) spp. ticks economically impact on cattle production in
Africa and other tropical and subtropical regions of the world. Tick vaccines constitute a cost-
effective and environmentally friendly alternative to tick control. The R. microplus Bm86 protective
antigen has been produced by recombinant DNA technology and shown to protect cattle against
tick infestations.
Results:  In this study, the genes for Bm86 (R. microplus), Ba86 (R. annulatus) and Bd86 (R.
decoloratus) were cloned and characterized from African or Asian tick strains and the recombinant
proteins were secreted and purified from P. pastoris. The secretion of recombinant Bm86 ortholog
proteins in P. pastoris allowed for a simple purification process rendering a final product with high
recovery (35–42%) and purity (80–85%) and likely to result in a more reproducible conformation
closely resembling the native protein. Rabbit immunization experiments with recombinant proteins
showed immune cross-reactivity between Bm86 ortholog proteins.
Conclusion: These experiments support the development and testing of vaccines containing
recombinant Bm86, Ba86 and Bd86 secreted in P. pastoris for the control of tick infestations in
Africa.
Background
Rhipicephalus (Boophilus) spp. ticks are distributed in trop-
ical and subtropical regions of the world with range
expansion for some species due to changes in climatic
conditions [1-3]. Infestations with the cattle tick, Rhipi-
cephalus (Boophilus) microplus, economically impact cattle
production by reducing weight gain and milk production,
and by transmitting pathogens that cause babesiosis
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(Babesia bovis and B. bigemina) and anaplasmosis (Ana-
plasma marginale) [4]. R. annulatus and R. decoloratus also
affect cattle production and vector pathogens in regions of
Latin America, Africa or Asia [2].
Control of tick infestations has been difficult because ticks
have few natural enemies. Integrated tick management
strategies include the adaptation of different control
methods to a geographic area. A major component of inte-
grated tick control methods is the application of acari-
cides. However, use of acaricides has had limited efficacy
in reducing tick infestations and is often accompanied by
serious drawbacks, including the selection of acaricide-
resistant ticks, environmental contamination and con-
tamination of milk and meat products with drug residues
[5]. Furthermore, development of new acaricides is a long
and expensive process. All of these issues reinforce the
need for alternative approaches to control tick infestations
[5]. Other approaches proposed for tick control have
included the use of hosts with natural resistance to ticks,
pheromone-impregnated decoys for attracting and killing
ticks, biological control agents and vaccines [6-8].
In the early 1990s, vaccines were developed that induced
immunological protection of vertebrate hosts against tick
infestations. These vaccines contained the recombinant R.
microplus Bm86 gut antigen [8-12]. Two vaccines using
recombinant Bm86 were subsequently registered in Latin
American countries (Gavac) and Australia (TickGARD)
during 1993–1997 [13]. These vaccines reduce the
number of engorging female ticks, their weight and repro-
ductive capacity. Thus the greatest vaccine effect was the
reduction of larval infestations in subsequent generations.
Vaccine controlled field trials in combination with acari-
cide treatments demonstrated that an integrated approach
resulted in control of tick infestations while reducing the
use of acaricides [12-14]. These trials demonstrated that
control of ticks by vaccination has the advantages of being
cost-effective, reducing environmental contamination
and preventing the selection of drug resistant ticks that
result from repeated acaricide application. In addition,
these vaccines may also prevent or reduce transmission of
pathogens by reducing tick populations and/or affecting
tick vectorial capacity [13-15].
Controlled immunization trials have shown that R. micro-
plus Bm86-containing vaccines also protect against related
tick species, R. annulatus and R. decoloratus [16-18]. How-
ever, R. microplus strain-to-strain variations in the suscep-
tibility to Bm86 vaccination have been reported, which
suggests that Bm86 sequence and/or tick physiological
differences may influence the efficacy of the vaccine [8,19-
22]. Therefore, the cloning, expression and vaccine formu-
lation with recombinant Bm86 from local tick strains may
be required for vaccine efficacy in some geographic
regions [20].
The recombinant Bm86 has been expressed in Escherichia
coli [10], Aspergillus nidulans and A. niger [23] and Pichia
pastoris [11,24,25]. Of these expression systems, P. pastoris
has been shown to be the more efficient for protein secre-
tion [26,27]. Furthermore, production of Bm86 in P. pas-
toris may increase the antigenicity and immunogenicity of
the recombinant antigen [28,29]. However, the process
previously reported for the production of recombinant
Bm86 in P. pastoris is not based on protein secretion but
on the expression of the antigen anchored to the yeast
membrane, making necessary the purification under
denaturing conditions followed by refolding of an antigen
with high number of disulfide bonds [24,25,30].
Recently,  R. decoloratus Bm86 orthologs were cloned,
expressed in E. coli and partially characterized [31]. How-
ever, the cloning and expression of recombinant R. annu-
latus and R. decoloratus Bm86 orthologs in P. pastoris have
not been reported.
The objectives of this study were (i) to clone and express
in P. pastoris the recombinant R. microplus, R. decoloratus
and R. annulatus Bm86 orthologs from African or Asian
tick strains and (ii) to simplify the Bm86 production proc-
ess by secreting recombinant proteins encoded by Bm86
orthologs in P. pastoris.
Results and Discussion
Cloning and sequence analysis of Bm86, Bd86 and Ba86
The Bm86 orthologs were cloned by RT-PCR from
Mozambique  R. microplus (Bm86), Israeli R. annulatus
(Ba86) and South African R. decoloratus (Bd86) tick
strains. Partial sequences were obtained and used to
search the NCBI nr database for sequence identity. The
first four BLAST hits (E-value = 0.0) showed that cloned
Bm86, Bd86 and Ba86 sequences were identical (90–97%
identity) to previously reported Bm86 (Australian
Yeerongpilly reference strain; GenBank accession number
M29321), Bm95 (Argentinean A strain; AF150891) and
Bd86-1 and Bd86-2 (Kenyan strain; DQ630523 and
DQ630524) sequences. The only fragment of 1,107
nucleotides previously reported for Ba86 (Mexican strain;
AF150897) had 99.9% identity to the Ba86 sequence
reported here with a single A × G substitution at position
1,674 (position 1 corresponds to the adenine in the initi-
ation codon of the M29321 reference sequence). The
Bm86 sequence of the Mozambique R. microplus strain
reported here had a deletion of 66 nucleotides between
positions 554 and 619 not found in other Bm86
sequences, which suggested that this region encoding for
22 amino acids may not be important for protein func-
tion. The Bd86 sequence of the South African R. decolora-
tus  strain had an 18 nucleotides insertion betweenBMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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positions 1,690 and 1,691, similar to Bd86-2 and three
nucleotides longer than in Bd86-1 [31].
Pairwise nucleotide and amino acid sequence alignments
were conducted between cloned Bm86, Ba86 and Bd86
sequences and those identified above to have identity to
these sequences (Table 1). The results showed that
sequence identity was higher between Bm86 and Ba86
than with Bd86 sequences.
Production and characterization of P. pastoris strains for 
the expression of recombinant Bm86, Bd86 and Ba86
The plasmids pPAMoz9, pPADec8 and pBaI were trans-
formed into P. pastoris strains GS115, KM71H and X33 for
expression of recombinant Bm86, Bd86 and Ba86 pro-
teins. Single colonies of P. pastoris transformants for each
gene were grown in an orbital shaker under induction
conditions. Culture supernatants were spotted on a nitro-
cellulose membrane for dot-blot analysis of recombinant
proteins. Expression of Bm86 and Bd86 was obtained in
GS115 and KM71H strains while Ba86 was expressed in
strain X33 only (Table 2). Expression levels varied
between 1.0 and 6.0 mg·L-1, representing 1.5% to 13.2%
of total proteins in the supernatant (Table 2). For recom-
binant Bm86 and Bd86, differences in expression levels
were not observed between GS115 and KM71H strains.
The highest expression levels were obtained for Ba86 in
strain X33 (Table 2). The recombinant strains
GS115Moz9-2, KM71HDec8-1 and X33pBaI-3 with high-
est expression levels of Bm86, Bd86 and Ba86, respec-
tively, were selected for fermentation scale up in a 5-L
bioreactor.
The GS115Moz9-2, KM71HDec8-1 and X33pBaI-3 high
expression strains had a MutS phenotype (Table 3). It has
been demonstrated that transformation of P. pastoris with
plasmids using the AOX1 expression system may lead to
three mutant phenotypes with regard to methanol utiliza-
tion [32]. The Mut+ phenotype grows on methanol at the
wild-type rate and requires high feeding rates of metha-
nol, the MutS phenotype has a disruption in the AOX1
gene and has a slower specific growth rate in methanol
and the Mut- is unable to grow in methanol. Although
transformation of X-33 and GS115 strains with linearized
constructs favor single crossover recombination at the
AOX1  locus and generates a Mut+  phenotype, double
crossover recombination that results in the disruption of
the wild-type AOX1 gene and the generation of a MutS
phenotype is possible. The P. pastoris strains with a MutS
phenotype grow slower in methanol but may be better
hosts for the secretion of recombinant proteins [33].
Expression of recombinant Ba86, Bd86 and Bm86 proteins 
in P. pastoris
The GS115Moz9-2, KM71HDec8-1 and X33pBaI-3 strains
were used for bench-top fermentation exploiting the
methanol utilization ability of P. pastoris strains in PM
medium. This medium was previously used for P. pastoris
fermentations to express high levels of recombinant
Bm86 [24,34].
The initial phase of the fermentation process (biomass
production phase) ended after 20–24 hrs and induction
of recombinant protein expression started at the onset of
methanol-adoption and utilization phases. As expected,
all strains behaved similarly when growing on glycerol as
the sole carbon source (Table 3). Cell densities before
induction and maximum growth rates on glycerol were
very similar and similar to those previously reported in P.
pastoris [33,35].
The selected fed-batch strategy to feed methanol was iden-
tical for all strains. Once glycerol used as carbon source in
the initial batch and fed-batch phases was consumed,
recombinant protein expression was induced by the addi-
tion of methanol to the culture medium. An exponential
growth phase was then observed during the next 20–24
hrs with maximum growth rates of 0.005, 0.002 and
0.003 h-1 for the strains GS115Moz9-2, KM71HDec8-1
and X33pBaI-3, respectively. However, after 24 hrs growth
Table 1: Nucleotide and amino acid sequence comparison between Bm86 orthologs.
Rm Bm86 
(M29321)
Rm Bm95 
(AF150891)
Rm Bm86 
(EU191620)
Ra Ba86 
(EU191621)
Rd Bd86-2 
(DQ630524)
Rd Bd86-1 
(DQ630523)
Rd Bd86 
(EU191622)
Rm Bm86 (M29321) 100 99 94 96 90 90 90
Rm Bm95 (AF150891) 98 100 94 96 90 90 90
Rm Bm86 (EU191620)* 93 92 100 92 86 87 86
Ra Ba86 (EU191621)* 94 94 90 100 91 91 91
Rd Bd86-2 (DQ630524) 85 86 82 87 100 96 97
Rd Bd86-1 (DQ630523) 86 86 82 88 94 100 96
Rd Bd86 (EU191622)* 86 87 82 88 96 94 100
Percent identity among nucleotide (above diagonal) and percent similarity among deduced amino acid (below diagonal) sequences between Bm86 
orthologs were determined. Sequences were aligned and percent identity/similarity was determined using the program AlignX. Abbreviations: Rm, R. 
microplus; Ra, R. annulatus; Rd, R. decoloratus. GenBank accession numbers are shown in parenthesis. The sequences reported in this study are 
identified wth an asterisk.BMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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in methanol, cells stop growing and a steady increase in
pO2 levels revealed that a stationary growth phase was
achieved. Nevertheless, total protein production contin-
ued to increase gradually to 274, 194 and 170 mg·L-1 for
the strains GS115Moz9-2, KM71HDec8-1 and X33pBaI-3,
respectively (Table 3 and Figs. 1 and 2).
In this first approach to obtain recombinant Bm86, Bd86
and Ba86 secreted to the culture medium, methanol was
supplied at 1 ml·h-1·L of the initial fermentation volume
for the first two hrs and then methanol supply was
increased in 10% increments every 30 min to a rate of 3
ml·h-1·L. This strategy probably did not allow maintain-
ing a steady concentration of methanol throughout the
whole fermentation process and either starvation or accu-
mulation of methanol could have occurred. This fact may
explain lower growth rates and expression levels of recom-
binant Bm86, Bd86 and Ba86 when compared to the 65
g·L-1 dry weight and 1.5 g·L-1 of recombinant protein pre-
viously reported for membrane-bound Bm86 in P. pastoris
[11,24,34]. These results suggest that recombinant Bm86,
Bd86 and Ba86 protein expression levels may be increased
by the optimization of the fermentation and methanol
induction processes.
Table 2: Screening for Bm86, Bd86 and Ba86 expression in the culture supernatant of P. pastoris transformants.
Recombinant strain Parental strain Recombinant 
protein
Total protein 
concentration (mg·L-1)a
Recombinant protein 
concentration (mg·L-1)b
% of total 
proteinc
GS115Moz9-1 GS115 Bm86 66.5 3.0 4.5
GS115Moz9-2* GS115 Bm86 65.5 3.3 5.0
GS115Moz9-3 GS115 Bm86 65.3 1.0 1.5
KM71HMoz9-1 KM71H Bm86 66.3 1.0 1.5
KM71HMoz9-2 KM71H Bm86 66.8 3.0 4.5
KM71HMoz9-3 KM71H Bm86 64.8 1.5 2.3
GS115Dec8-1 GS115 Bd86 64.4 1.0 1.6
GS115Dec8-2 GS115 Bd86 66.4 1.5 2.3
GS115Dec8-3 GS115 Bd86 66.0 1.5 2.3
KM71HDec8-1* KM71H Bd86 66.0 2.0 3.0
KM71HDec8-2 KM71H Bd86 63.4 1.5 2.4
KM71HDec8-3 KM71H Bd86 63.5 1.0 1.6
X33pBaI 1 X33 Ba86 49.7 1.0 2.0
X33pBaI 2 X33 Ba86 45.5 1.0 2.2
X33pBaI 3* X33 Ba86 45.4 6.0 13.2
X33pBaII 1 X33 Ba86 55.8 5.5 9.8
X33pBaII 2 X33 Ba86 48.3 5.0 10.4
X33pBaII 3 X33 Ba86 46.9 4.0 8.5
The experiments were conducted twice with similar results.
aDetermined using the Bradford method with BSA as standard [49].
bDetermined by semi-quantitative analysis in dot-blots using a standard curve constructed with known amounts of recombinant Bm86 extracted 
from Gavac (Revetmex).
cDetermined as the percent of recombinant protein in total preoteins.
*Recombinant strains with highest Bm86, Bd86 and Ba86 concentration in the culture supernatant were selected for fermentation and protein 
production.
Table 3: Characterization of the fermentation process for the secretion of recombinant Bm86, Bd86 and Ba86.
Recombinant 
strain
Mut 
phenotype
O.D. 600 nm before 
induction
μmax in glycerol 
(h-1)a
μmax in methanol 
(h-1)b
Total protein 
concentration 
(mg·L-1)c
Recombinant protein
Concentration 
(mg·L-1)c
Purity 
(%)c
Productivity 
(mg·L-1·h-1)c
GS115Moz9-2 MutS 115 0.181 0.005 274 150 55 2.1
KM71HDec8-1 MutS 125 0.182 0.002 194 110 57 1.5
X33pBaI 3 MutS 125 0.178 0.003 170 112 66 1.6
aThe maximum growth rate (μmax) was determined during the exponential growth phase on glycerol in batch and fedbatch modes.
bThe maximum growth rate (μmax) was determined during the exponential growth phase on methanol (first 20–24 hrs after induction).
cDetermined in the culture medium 72 hrs after induction with methanol using the Bradford method with BSA as standard [49] and the Experion semiautomated 
electrophoresis system (Bio-Rad, Hercules, CA, USA).BMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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The presence of recombinant proteins in the culture
supernatant was demonstrated at the end of the fermenta-
tion process by SDS-PAGE and Western blot (Fig. 3).
Recombinant Bm86, Bd86 and Ba86 secreted in P. pastoris
appeared in SDS-PAGE and Western blots as a major wide
band with a size range of 100 to 110 kDa and smaller deg-
radation fragments (Fig. 3). The recombinant Bm86 pre-
viously expressed in P. pastoris also had degradation
products and a major wide band, but with a size ranging
from 90 to 100 kDa [11]. These differences in estimated
molecular weight of the proteins may be due to strain dif-
ferences in glycosylation, which is responsible for the
wide appearance of the protein band in the SDS-PAGE
and Western blot [11].
Protein recovery and purification
To obtain a clarified supernatant for recombinant protein
purification, a primary centrifugation step was performed
at 3,900 × g. Due to the fact that P. pastoris culture centrif-
ugation at g-forces between 3,000–5,000 results in a sig-
nificant product entrainment [36], a washing step of cell
pellets was made for the full recovery of secreted proteins.
P. pastoris secretes few autologous proteins [37]. There-
fore, heterologous protein secretion serves as the major
first step in recombinant protein purification. However,
unclear supernatants and recombinant protein purities
ranging between 55% and 66% suggested the presence of
contaminants in the supernatant after cell separation
Secretion of recombinant Bm86, Bd86 and Ba86 by P. pastoris Figure 3
Secretion of recombinant Bm86, Bd86 and Ba86 by 
P. pastoris. Silver stained SDS-PAGE (lanes 1–5) and West-
ern blot analysis (lanes 6–10) of the fermentation culture 
supernatants after 72 hrs growing in methanol. Samples of 15 
μL were loaded in each well. Membranes for Western blot 
were probed with serum from rabbits immunized with con-
trol Bm86 (Gavac; Revetmex) diluted 1:1000. Membranes 
were then washed three times with TBS and incubated with 
an anti-rabbit IgG HRP conjugate (Sigma-Aldrich) diluted 
1:1000 in TBS. After washing the membranes again, color 
was developed using TMB stabilized substrate for HRP 
(Promega). Lanes 1 and 6: molecular weight markers (MW; 
ColorBurst, Sigma-Aldrich). Lanes 2 and 7: culture superna-
tants of the P. pastoris GS115/Albumin negative control 
strain. Lanes 3 and 8, 4 and 9, and 5 and 10: culture superna-
tants of X33pBaI-3 (Ba86), GS115Moz9-2 (Bm86) and 
KM71HDec8-1 (Bd86) strains, respectively. The position of 
recombinant proteins is indicated with arrows.
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Characterization of the growth of P. pastoris strains during  the fermentation process Figure 1
Characterization of the growth of P. pastoris strains 
during the fermentation process. Time profile of optical 
density measurements of P. pastoris strains GS115Moz9-2, 
KM71HDec8-1 and X33pBaI-3 expressing recombinant 
Bm86, Bd86 and Ba86, respectively.
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(Table 4). This observation suggested that probably cell
lysis occurred during the stationary phase of the fermenta-
tion process due to suboptimal growth conditions. Cell
lysis during the fermentation may have contributed to
protein degradation, thus affecting recombinant protein
yield and reinforcing the need for optimization of the fer-
mentation process to reduce protein degradation and
increase expression levels.
It has been demonstrated in previous cell fractionation
experiments of P. pastoris that a wide range of particles
densities and sizes are present in a disrupted suspension
of the yeast [38,39]. Therefore, to separate particles in sus-
pension from secreted recombinant proteins, superna-
tants were filtered throughout 5, 0.45 and 0.22 μm
filtration systems, which resulted in 20–25% increase in
recombinant protein purity (Table 4). Finally, size exclu-
sion and diafiltration through a 50 kDa cut-off membrane
resulted in 80–85% pure recombinant proteins (Table 4
and Fig. 4).
The purity of recombinant proteins reported herein after
protein secretion and a simple centrifugation-filtration
purification process was higher than that obtained for
membrane-bound Bm86 [24,34]. The purification of the
membrane-bound Bm86 required cell disruption, wash-
ing of cell pellet, denaturation, renaturation and protein
precipitation procedures [24,34]. In spite of the high level
expression obtained during fermentation [11,34] and the
optimization of the purification process [24,40-43] for
the membrane-bound Bm86, the secretion of recom-
binant Bm86 in P. pastoris reported herein allowed for
higher recovery and purity of recombinant protein after
purification.
Additionally, an important advantage of secreting recom-
binant proteins in P. pastoris, particularly for proteins with
complex structures and a high number of disulfide bonds
such as Bm86 [44], is that the isolation of a membrane-
bound form under denaturing conditions followed by
refolding is very unlikely to reform all disulfide bonds cor-
rectly and reproducibly. By contrast, if disulfide bond for-
mation occurs through the natural cell processing and
secretion machinery as reported herein, the product is
more likely to have a reproducible conformation closely
resembling the native protein.
The recombinant Bm86 has been expressed in E. coli [10],
A. nidulans and A. niger [23] and P. pastoris [11,24,25].
Other expression systems using arthropod cell lines have
been considered. However, despite recent advances in the
application of insect cell culture technology for the pro-
duction of recombinant proteins, the process is still more
expensive and difficult to scale-up when compared to pro-
teins expressed in E. coli and P. pastoris [45]. The secretion
of recombinant Bm86 ortholog proteins reported here in
P. pastoris is easy to scale-up, simple, reproducible and
likely to result in a product with high antigenicity and
immunogenicity [28,29].
Characterization of recombinant Bm86, Bd86 and Ba86
Although differences may exist in antigen recognition
between cattle and rabbits [46], rabbits have been proven
to recognize some Bm86 protective epitopes [11,47] and
were therefore considered a suitable host to evaluate
immune cross-reactivity between recombinant Bm86
ortholog proteins.
The purified recombinant Bm86, Bd86 and Ba86 were
adjuvated and used to immunize rabbits. The sera from
immune rabbits were used to evaluate by Western blot the
immune cross-reactivity between Bm86 ortholog pro-
teins. The results showed that recombinant Bm86, Bd86
and Ba86 contained cross-reactive epitopes (Fig. 5). These
results are in agreement with previous reports for Bd86
[31] and may explain, at least in part, the efficacy of the
Bm86-containing vaccine against R. annulatus and  R.
decoloratus  infestations [16-18]. However, despite
immune cross-reactivity between Bm86 ortholog pro-
teins, the differences in the efficacy of Bm86-containing
vaccines against different Rhipicephalus spp. may be attrib-
uted to differences in the sequence of protective epitopes
and/or physiological differences between tick species.
Only cattle vaccination experiments with the recombinant
antigens obtained here and challenging with homologous
and heterologous Rhipicephalus spp. could fully address
this question.
Conclusion
We have cloned and secreted in P. pastoris the recom-
binant R. microplus, R. decoloratus and R. annulatus Bm86
orthologs from African or Asian tick strains. To our knowl-
edge, this is the first study of Bm86, Bd86 and Ba86 secre-
tion in P. pastoris. The results reported herein have shown
that in P. pastoris, Bm86 ortholog recombinant proteins
are secreted and purified from the culture supernatant
with high yield and purity. The purification process for
secreted proteins was simpler than that described for
membrane-bound Bm86, which suggests the possibility
of simplifying the purification process for recombinant
Bm86 when secreted in P. pastoris. Additionally, secretion
of recombinant Bm86 ortholog proteins in P. pastoris is
likely to result in a more reproducible conformation
closely resembling the native protein. Finally, the prelim-
inary immunological characterization of recombinant
Bm86, Bd86 and Ba86 evidenced the presence of cross-
reactive epitopes among these proteins. These results sug-
gest that these recombinant antigens can be used for the
development of vaccines for the control of tick infesta-
tions in Africa. The control of livestock Rhipicephalus spp.B
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Table 4: Characterization of the recombinant Bm86, Bd86 and Ba86 purification process.
Purification stages Bm86 Bd86 Ba86
Total protein 
conc. (mg·L-1)
Rec. protein 
conc. (mg·L-1)
Purity 
(%)
Recovery 
(%)
Total protein 
conc. (mg·L-1)
Rec. protein 
conc. (mg·L-1)
Purity 
(%)
Recovery 
(%)
Total protein 
conc. (mg·L-1)
Rec. protein 
conc. (mg·L-1)
Purity 
(%)
Recovery 
(%)
Fermentation supernatant 274 150 55 --- 194 110 57 --- 170 112 66 ---
Culture separation and 
microfiltration
1 3 7 9 6 7 06 0 8 4 6 3 7 55 5 9 9 7 7 7 8 6 2
Ultrafiltration and 
diafiltration
407 326 80 35 451 370 82 42 370 314 85 40
Abbreviations: conc., concentration; rec., recombinant.BMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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infestations in Africa would contribute to improve animal
health and production in this region.
Methods
Media and solutions
All reagents used in this work were purchased from Sigma-
Aldrich (St Louis, MO, USA) or VWR International Euro-
lab S.L. (Mollet del Vallés, Barcelona, Spain). The compo-
sitions of the media used in this study were as follows:
Minimal methanol medium (MM): 13.4 g·L-1 yeast nitro-
gen base with ammonium sulphate and without amino
acids (YNB); 0.0004 g·L-1biotin; 15 g·L-1 agar and 0.5%
methanol.
Minimal methanol medium + Histidine (MMH): 13.4
g·L-1 YNB; 0.0004 g·L-1 biotin; 15 g·L-1 agar; 0.04 g·L-1
histidine and 0.5% methanol.
Minimal dextrose medium (MD): 13.4 g·L-1 YNB; 0.0004
g·L-1 biotin; 15 g·L-1 agar and 20 g·L-1 dextrose.
Minimal dextrose medium + Histidine (MDH): 13.4 g·L-
1 YNB; 0.0004 g·L-1 biotin; 15 g·L-1 agar; 20 g·L-1 dextrose
and 20 g·L-1 dextrose.
Yeast Extract Peptone medium (YP): 10 g·L-1 yeast extract
and 20 g·L-1 peptone.
Yeast Extract Peptone Dextrose medium (YPD): 10 g·L-1
yeast extract; 20 g·L-1 peptone and 20 g·L-1 glucose.
Yeast Extract Peptone Dextrose Sorbitol medium (YPDS):
10 g·L-1yeast extract; 20 g·L-1 peptone; 20 g·L-1 glucose;
182 g·L-1 sorbitol and 20 g·L-1 agar.
Trace element solution (TES): 2.0 g·L-1 ZnSO4 × 7H2O;
0.02 g·L-1 CuSO4 × 5H2O; 0.08 g·L-1 KI; 0.3 g·L-1 MnSO4
× H2O; 0.19 g·L-1Na2MoO4 × H2O; 0.02 g·L-1 H3BO3 and
2.9 g·L-1 FeCl3.
Vitamin solution (VT): 0.4 g·L-1 calcium pantothenate;
0.4 g·L-1 tyamine; 4 g·L-1 myo-inositol; 0.1 g·L-1 nicotinic
acid; 0.4 g·L-1 pyridoxine and 0.4 g·L-1 biotin.
Production medium (PM): 13 g·L-1 KH2PO4; 8.75 g·L-1
(NH4)2SO4; 4.5 g·L-1 MgSO4; 0.5 g·L-1 CaCl2 × 2H2O; 2.5
g·L-1 yeast extract; 5 ml·L-1 TES and 5 ml·L-1 VT.
Immune cross-reactivity between Bm86 ortholog proteins Figure 5
Immune cross-reactivity between Bm86 ortholog 
proteins. Western blot analysis of the purified recombinant 
Ba86 (lane 1), Bd86 (lane 2) and Bm86 (lane 3) proteins. On 
each well 1.5 μg proteins were loaded. Membranes were 
probed with serum from rabbitts immunized with recom-
binant Ba86 (A), Bd86 (B) and Bm86 (C) diluted 1:5000. 
Membranes were washed three times with TBS and incu-
bated with an anti-rabbit IgG HRP conjugate (Sigma-Aldrich) 
diluted 1:1000 in TBS. After washing the membrane again, 
color were developed using TMB stabilized substrate for 
HRP (Promega). MW: molecular weight marker (ColorBurst, 
Sigma-Aldrich). The position of recombinant proteins is indi-
cated with arrows.
100 kDa
60 kDa
45 kDa
MW     1         2       3        1        2        3   1        2       3    
A                    B                      C
100 kDa
60 kDa
45 kDa
100 kDa
60 kDa
45 kDa
MW     1         2       3        1        2        3   1        2       3    
A                    B                      C
Characterization of purified recombinant proteins Figure 4
Characterization of purified recombinant proteins. 
Western blot analysis of the purified recombinant Bm86 
(lane 2), Bd86 (lane 3) and Ba86 (lane 4) proteins. On each 
well, 3.5 μg proteins were loaded. Membranes were probed 
with serum from rabbits immunized with control Bm86 
(Gavac; Revetmex) diluted 1:1000. Membranes were then 
washed three times with TBS and incubated with an anti-rab-
bit IgG HRP conjugate (Sigma-Aldrich) diluted 1:1000 in TBS. 
After washing the membranes again, color was developed 
using TMB stabilized substrate for HRP (Promega). Lane 1: 
molecular weight markers (MW; ColorBurst, Sigma-Aldrich). 
The position of recombinant proteins is indicated with 
arrows.
220 kDa
100 kDa
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45 kDa
1       2       3     4
220 kDa
100 kDa
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Cloning of R. microplus, R. annulatus and R. decoloratus 
Bm86 orthologs and sequence analysis
Tick strains were obtained from laboratory colonies main-
tained at the Utrecht Centre for Tick-borne Diseases,
Department of Infectious Diseases and Immunology, Fac-
ulty of Veterinary Medicine, Utrecht University, Utrecht,
The Netherlands. Originally, tick strains were collected
from infested cattle in Mozambique (R. microplus), Israel
(R. annulatus) and South Africa (R. decoloratus).
Total RNA was extracted from the viscera of partially fed
R. annulatus and R. microplus females and from eggs of R.
annulatus  and  R. decoloratus using TriReagent (Sigma-
Aldrich, St Louis, MO, USA) and following manufacturer's
recommendations. Bm86 (R. microplus), Ba86 (R. annula-
tus) and Bd86 (R. decoloratus) coding regions (nucleotides
58–1884 of the coding region of Bm86 reference
sequence; GenBank accession number M29321) lacking
the signal peptide and GPI anchor sequences were ampli-
fied by RT-PCR. The RT-PCR was done using 10 pmol of
each primer (CZABM5: 5'-A CTC GAG AAA AGA GAG
TCA TCC ATT TGC TCT GAC TTC GG and CZABM3: 5'-A
TCT AGA TTA AGC ACT TGA CTT TCC AGG ATC TG;
Bm86 homologous regions are underlined) in a 50-μl vol-
ume (1.5 mM MgSO4, 1 × avian myeloblastosis virus
(AMV) RT/Thermus flavus (Tfl) reaction buffer, 0.2 mM
each deoxynucleoside triphosphate (dNTP), 5 u AMV RT,
5 u Tfl DNA polymerase) employing the Access RT-PCR
system (Promega, Madison, WI, USA). Reactions were
performed in an automated DNA thermal cycler (Techne
model TC-512, Cambridge, England, UK). RNA was
reverse transcribed for 45 min at 45°C prior to PCR con-
sisting of an initial step of 2 min at 94°C followed by 35
cycles of a denaturing step of 30 sec at 94°C and an
annealing-extension step of 2 min at 68°C. Control reac-
tions were done using the same procedures, but without
RNA added to control contamination of the PCR. PCR
products were electrophoresed on 1% agarose gels to
check the size of amplified fragments by comparison to a
DNA molecular weight marker (1 Kb Plus DNA Ladder,
Promega). The amplicon was resin purified (Wizard,
Promega) and cloned into pGEM-T vector (Promega).
Partial sequences of cloned Bm86 orthologs were
obtained by double-stranded dye-termination cycle
sequencing (Core Sequencing Facility, Department of Bio-
chemistry and Molecular Biology, Noble Research Center,
Oklahoma State University and Secugen S.L, Madrid,
Spain). At least three clones from independent PCR reac-
tions were sequenced for each gene. Multiple sequence
alignment was performed using the program AlignX (Vec-
tor NTI Suite V 8.0, InforMax, Invitrogen, Carlsbad, CA,
USA) with an engine based on the Clustal W algorithm
[48]. Searches for sequence similarity were performed at
the ncbi with the BLASTN program against the nonredun-
dant sequence database nr.
The GenBank accession numbers for Bm86 (R. microplus),
Ba86 (R. annulatus) and Bd86 (R. decoloratus) are
EU191620–EU191622.
Construction of expression plasmids
Bm86, Ba86 and Bd86 coding regions were excised from
pGEM-T by Xho I and Xba I digestion (restriction sites
introduced during PCR by CZABM5 and CZABM3 prim-
ers, respectively) and cloned into P. pastoris expression
vector pPICZαA (Invitrogen) digested with Xba I and Xho
I. In this way, Bm86 orthologs were cloned under the con-
trol of the alcohol oxidase (AOX1) promoter, in frame
with the yeast alfa-factor secretion signal but without the
C-terminal c-myc/His tag due to a translation termination
site introduced by CZABM3 primer during PCR. The
expression constructs were sequenced at both ends and
selected constructs with correct sequences were named
pPAMoz9 (Bm86), pPADec8 (Bd86) and pBaI (Ba86) and
used for transformation of P. pastoris.
Pichia pastoris transformation and screening for 
recombinant protein expression
Expression plasmids were linearized by restriction with
Sac  I and transformed into P. pastoris strains GS115,
KM71H and X33 (Invitrogen) by electroporation as
described [49]. Transformants were selected on YPDS
plates containing 100 μg·ml-1 Zeocin and incubated at
30°C. A functional assay to directly screen for high expres-
sion recombinant clones was made by culturing the trans-
formants in an orbital shaker at 250 rpm and 30°C. Single
colonies were inoculated in 1 ml YPDS containing 100
μg·ml-1  Zeocin and grown overnight. Cultures were
divided into two parts of 500 μl each. Five hundred μl
were transferred to 5 ml fresh YP medium with 20 g·L-1
glycerol, grown for 24 hrs and inoculated into 250 ml
fresh YP medium supplemented with 20 g·L-1 glycerol.
Growth in glycerol was resumed after 24 hrs and then
methanol was added daily to 1% (v/v) during the course
of induction. After 5 days growing on methanol, superna-
tants were collected by centrifugation for 15 min at
15,000 × g in a Beckman Allegra™ X-22R centrifuge, rotor
F2402H (Beckman-Coulter, Palo Alto, CA, USA) and dot
blots were made to screen for expression of recombinant
proteins. The other 500 μl were also transferred to 5 ml
fresh YP medium with 20 g·L-1 glycerol, grown for 24 hrs
and mixed with glycerol to 250 g·L-1. Long term stocks
were prepared as 100 μl aliquots and stored frozen at -
80°C.
Analysis of the Mut phenotype in P. pastoris transformed 
strains
The high expression transformants of X33 and GS115
strains were analyzed for Mut+ or MutS phenotype using
the functional assay described in the Invitrogen user's
manuals K1710-01 and K1750-01 [49]. The KM71HBMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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strain always produces a MutS phenotype [49]. Briefly, 50
μl from the long term stocks of the high expression X33
and GS115 transformants were streaked in YPDS plates
containing 100 μg·ml-1 Zeocin and incubated at 30°C for
24 hrs. One colony of each transformant was streaked in
both MMH and MDH plates for the GS115 and X33
strains. To differentiate Mut+ from MutS, control GS115/
Albumin (MutS) and GS115/pPicz/lacZ (Mut+) strains
(Invitrogen) were streaked in the MMH and MDH plates.
Plates were incubated at 30°C for 3 days and cell growth
was observed and compared to controls.
Fermentation process
Pre-inoculums and inoculums for bioreactor cultures
were grown in a shaker at 30°C and 250 rpm. Two 100 μl
long term stock vials were seeded in 1 ml YP medium,
grown for 12 hrs and transferred into 4 × 50 ml tubes con-
taining 5 ml of YP medium with 20 g·L-1 glycerol. After 24
hrs, cultures were mixed again and 5 ml were used to inoc-
ulate 2 L Erlenmeyer flasks containing 250 ml of YP
medium with 20 g·L-1glycerol. Cells were grown to an
O.D.600 nm between 15 and 20 and then cultures were
inoculated into a 5-L working volume Biostat B bioreactor
(B. Braun Biotech, Melsungen, Germany) containing 3.5 L
of PM with 40 g·L-1 glycerol.
During the fermentation process, temperature was kept at
30°C and dissolved oxygen was maintained at 30% satu-
ration by regulating agitation and aeration rates. A three-
phase cultivation protocol was used in the fermentation.
The glycerol growth phase included a 12 to 14 hrs batch
stage from the starting point followed by a 10 to 12 hrs
glycerol fed-batch stage. A glycerol solution of 50% (v/v)
was added to the fermentor for 4 hrs to reach an equiva-
lent total quantity of 60 g·L-1 in the culture medium.
Upon exhaustion of glycerol, indicated by a sharp increase
in dissolved oxygen, methanol induction was made by
adding 1% (v/v) methanol to the culture medium and 3
hrs later the fed-batch phase was started by feeding meth-
anol according to the P. pastoris Fermentation Process
Guideline [49]. The pH was allowed to drop to 3.5 during
the whole glycerol phase and it was maintained in this
value by the addition of NH4OH. Prior to methanol
induction, pH was adjusted and maintained at 5.5 by add-
ing NH4OH or H3PO3. Throughout the fermentation
processes, supplements of 20 ml TES and VT solutions
were added to the culture medium every 24 hrs. Addition-
ally, GS115 strain cultures were supplemented with 0.04
g·L-1 L-Histidine every 24 hrs.
Biomass analysis during fermentation
Time-course samples were withdrawn from the fermentor
at regular intervals to check growth rate and protein con-
centration in the supernatant. Cell density was expressed
as O.D.600 nm, either measured as grams of wet weight per
litter broth (O.D.600 nm = 1.39 × wet weight (g·L-1) -
27.26), which was obtained by centrifugation of the sam-
ples at 15,000 × g for 15 min or measured directly in the
culture medium. Total protein concentration in the cul-
ture medium was quantified using the Bradford method
with BSA as standard [50].
Cells harvesting, recovery and purification of recombinant 
proteins
Cultures from the 5-L fermentor were centrifuged at 3,900
× g for 15 min in a Beckman Allegra™ X-22R centrifuge,
rotor SX4250 (Beckman-Coulter) to separate cells. Super-
natants were then collected and filtered through a tandem
filtration system with a 20 μm cartridge (Sartorius AG,
Goettingen, Germany), 5 μm and 0.45-0.22 μm cartridges
(Millipore, Billerica, MA, USA) and checked for total and
recombinant protein content using the Bradford method
with BSA as standard [50] and the Experion semiauto-
mated electrophoresis system (Bio-Rad, Hercules, CA,
USA). For the Experion, 4 μl of denatured proteins were
loaded into a Pro 260 Chip and protein concentration was
determined following manufacturer's recommendations.
Recombinant proteins were separated by size exclusion
using a Sartocon® Slice 200 ultrafiltration system having a
Hydrosart membrane with a molecular weight cut-off of
50 kDa (Sartorius). Finally, protein solutions were con-
centrated and diafiltrated against four volumes of phos-
phate buffer pH 8.3 using a centrifugal concentrator
VIVACELL 100 (50 kDa cut-off; Sartorius) in a Beckman
Allegra™ X-22R centrifuge, rotor SX4250 (Beckman-Coul-
ter) at 3,900 × g.
Vaccine formulation and analysis
Prior to adjuvation of the vaccine, protein solutions were
adjusted to a concentration of 120 μg·ml-1 and filtered
through 0.45 and 0.22 μm cartridges (Sartorius AG) under
sterile conditions in a laminar flow to obtain a sterile anti-
gen solution. Adjuvation was made by mixing a solution
of anhydromannitoletheroctodecenoate (Montanide ISA
50 V; Seppic, Paris, France) with the recombinant protein
solution in batch-by-batch processes using a high-speed
mixer Heidolph DIAX 900 (Heidolph Elektro, Kelheim,
Germany) at 8,000 rpm and the vaccine was filled manu-
ally under sterile conditions in glass bottles of 20 ml
(Wheaton, Millville, NJ, USA). Quality controls were
made by testing mechanical and thermal stability of vac-
cine emulsions as described by Canales et al. [24].
Rabbit immunization with recombinant proteins
Two New Zealand White rabbits per group was each
immunized with 3 doses (weeks 0, 4 and 8) containing 50
μg/dose of purified recombinant proteins formulated as
described above or Gavac (Revetmex, Mexico City, Mex-
ico) as control. Rabbits were injected subcutaneously with
1 ml/dose using a 1 ml tuberculin syringe and a 27 1/2GBMC Biotechnology 2008, 8:14 http://www.biomedcentral.com/1472-6750/8/14
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needle. Two weeks after the last immunization, blood
samples were collected from each rabbit into sterile tubes
and maintained at 4°C until arrival at the laboratory.
Serum was then separated after centrifugation and stored
at -20°C. Rabbits were cared for in accordance with stand-
ards specified in the Guide for Care and Use of Laboratory
Animals.
SDS-PAGE, dot blot and Western blot analyses
Protein samples were analyzed by denaturing SDS-PAGE
with a 12% PAGEgel-SDS cassette gel (PAGE-gel Inc, San
Diego, CA, USA) under reducing conditions. Protein
bands were visualized by either Coomassie Brilliant Blue
R250 or silver staining. Samples were treated with dithio-
threitol (DTT) reducer (PAGE-gel Inc.), heated in boiling
water for 5 min before loading onto the gel and electro-
phoresed for 80 min at 90 mA constant current.
Electrophoretic transfer of proteins from gels to nitrocel-
lulose membranes (PROTRAN BA85; Schleicher and
Schuell, Dassel, Germany) for Western blot analysis was
carried out in a Minie-Genie Electroblotter semi-dry trans-
fer unit (Idea Scientific, Corvallis, OR, USA) according to
manufacture's protocol. Protein samples of 2 μl were
absorbed onto nitrocellulose membrane by gravity flow
to perform the dot blot analysis. A standard curve was
constructed with known amounts of recombinant Bm86
extracted from Gavac (Revetmex) and was used for semi-
quantitative analysis in dot-blots. The supernatant of the
GS115/Albumin strain (Invitrogen) grown under the
same conditions was used as a negative control in both
dot- and Western-blots. Membranes for dot or Western
blots were blocked with 5% skim milk for 1 hr at room
temperature, washed three times in TBS (25 mmol/L
Tris·HCl, 150 mmol/L NaCl, pH 7.6) and probed with
sera from rabbits immunized with Gavac (Revetmex)
(1:1000 dilution) or recombinant proteins (1:5000 dilu-
tion) as described above. The antisera were diluted in 3%
BSA in TBS. Membranes were then washed three times
with TBS and incubated with an anti-rabbit IgG horserad-
ish peroxidase (HRP) conjugate (Sigma-Aldrich) diluted
1:1000 in TBS. After washing the membranes again, color
was developed using TMB stabilized substrate for HRP
(Promega).
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